Clinical characteristics and main echocardiographic measurements at baseline
| Trimetazidine treated group (n = 30) | Control group (n = 31) | |
|---|---|---|
| Parametric data are expressed as mean (SD) and non-parametric data as number of patients (%). | ||
| ACE, angiotensin converting enzyme. | ||
| Age (years) | 67 (5.5) | 69 (7) |
| Men/women | 17/13 | 18/13 |
| Drug treatment | ||
| Diuretics | 30 (100%) | 31 (100%) |
| ACE inhibitors or angiotensin II antagonists | 27 (90%) | 28 (90.3%) |
| Digoxin | 8 (26.7%) | 7 (22.6%) |
| Nitrates | 6 (20%) | 8 (25.8%) |
| β Blockers | 15 (50%) | 18 (58.1%) |
| Calcium antagonists | 6 (20%) | 6 (19.4%) |
| Aspirin | 22 (73.3%) | 20 (64.5%) |
| Echocardiography | ||
| Left ventricular volume | ||
| End systolic (ml/m2) | 91 (18) | 88 (15) |
| End diastolic (ml/m2) | 133 (30) | 127 (22) |
| Ejection fraction (%) | 30 (6) | 31 (8) |
| Mitral regurgitation (light to moderate) | 17 (56.7%) | 16 (51.6%) |